Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S, Furuya N, Nakamura A, Shiihara J, Nakachi I, Tanaka H, Nakao M, Minato K, Seike M, Sasaki S, Kisohara A, Takeuchi S, Honda R, Takamura K, Kagamu H, Yoshimura K, Kobayashi K, Kikuchi T. Watanabe S, et al. Among authors: yoshimura k. Eur J Cancer. 2024 Jan;197:113469. doi: 10.1016/j.ejca.2023.113469. Epub 2023 Dec 2. Eur J Cancer. 2024. PMID: 38061214 Clinical Trial.
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L).
Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. Wakuda K, et al. Among authors: yoshimura k. JTO Clin Res Rep. 2023 Oct 12;4(12):100587. doi: 10.1016/j.jtocrr.2023.100587. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046380 Free PMC article.
Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Ogawa A, Kawamoto H, Hara J, Kikuta A, Ogawa C, Hiraga H, Yoshimura K, Miyairi K, Omori R, Ro T, Kamei Y, Kimura T. Ogawa A, et al. Among authors: yoshimura k. Cancer Chemother Pharmacol. 2024 Jul;94(1):89-101. doi: 10.1007/s00280-024-04664-6. Epub 2024 Mar 13. Cancer Chemother Pharmacol. 2024. PMID: 38478074 Free PMC article. Clinical Trial.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: yoshimura k. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
Successful treatment of young childhood standard-risk hepatoblastoma with cisplatin monotherapy using a central review system.
Saeki I, Ida K, Kurihara S, Watanabe K, Mori M, Hishiki T, Yokoi A, Fujimura J, Honda S, Nogami Y, Iehara T, Kazama T, Sekiguchi M, Kitagawa N, Matsumura R, Nomura M, Yamada Y, Hanaki R, Kaneda H, Takama Y, Inoue T, Tanaka Y, Miyazaki O, Nagase H, Takimoto T, Yoshimura K, Hiyama E. Saeki I, et al. Among authors: yoshimura k. Pediatr Blood Cancer. 2024 Nov;71(11):e31255. doi: 10.1002/pbc.31255. Epub 2024 Aug 10. Pediatr Blood Cancer. 2024. PMID: 39126361
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).
Nakayama S, Yoshizawa A, Tsurutani J, Yoshimura K, Aoki G, Iwamoto T, Nagase H, Sugimoto N, Kobayashi K, Izumi S, Kato T, Miyazaki Y, Kurihara Y, Taira N, Aihara T, Kikawa Y, Mukai H. Nakayama S, et al. Among authors: yoshimura k. Breast Cancer. 2025 Jan;32(1):177-185. doi: 10.1007/s12282-024-01648-5. Epub 2024 Nov 18. Breast Cancer. 2025. PMID: 39556171
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG). Komori A, et al. Among authors: yoshimura k. Gastric Cancer. 2024 Dec 31. doi: 10.1007/s10120-024-01579-2. Online ahead of print. Gastric Cancer. 2024. PMID: 39738793
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Kudo M, et al. Among authors: yoshimura k. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. Gut. 2020. PMID: 31801872 Free PMC article. Clinical Trial.
Treatment with vonoprazan for 3 weeks is not inferior to 8 weeks for the management of gastric ESD: a multicenter noninferiority randomized study.
Kato M, Hosoe N, Gotoda T, Kusano C, Kuramochi M, Yoshida H, Kimoto Y, Okamura Y, Imaeda H, Ito T, Miyamoto Y, Horii T, Mori H, Morohoshi Y, Ohno A, Kishino R, Kubosawa Y, Yoshimura K, Yahagi N, Kanai T. Kato M, et al. Among authors: yoshimura k. J Gastroenterol. 2023 Apr;58(4):358-366. doi: 10.1007/s00535-023-01966-z. Epub 2023 Feb 13. J Gastroenterol. 2023. PMID: 36781490 Clinical Trial.
2,874 results